Thomas N Seyfried

List of Publications by Year
in descending order

154	9,741	31976	42399
papers	citations	53 h-index	92 g-index

157	157	157	11145
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis. Brain, 2022, 145, 655-669.	7.6	7
2	Proline Oxidation Supports Mitochondrial ATP Production When Complex I Is Inhibited. International Journal of Molecular Sciences, 2022, 23, 5111.	4.1	12
3	Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clinical Nutrition, 2021, 40, 751-758.	5.0	53
4	Gene expression in the epileptic (EL) mouse hippocampus. Neurobiology of Disease, 2021, 147, 105152.	4.4	17
5	Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report. Frontiers in Nutrition, 2021, 8, 682243.	3.7	13
6	Light- and Melanin Nanoparticle-Induced Cytotoxicity in Metastatic Cancer Cells. Pharmaceutics, 2021, 13, 965.	4.5	6
7	Fiveâ€day waterâ€only fasting decreased metabolicâ€syndrome risk factors and increased antiâ€aging biomarkers without toxicity in a clinical trial of normalâ€weight individuals. Clinical and Translational Medicine, 2021, 11, e502.	4.0	11
8	Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle. Molecular Metabolism, 2021, 54, 101389.	6.5	15
9	Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?. Metabolites, 2021, 11, .	2.9	4
10	Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?. Metabolites, 2021, 11, 572.	2.9	21
11	Chemical mutagenesis of a GPCR ligand: Detoxifying â€œinflammo-attractionâ€•to direct therapeutic stem cell migration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31177-31188.	7.1	10
12	On the Origin of ATP Synthesis in Cancer. IScience, 2020, 23, 101761.	4.1	65
13	Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: a randomized controlled clinical trial. Nutrition Journal, 2020, 19, 87.	3.4	42
14	Caprylic (Octanoic) Acid as a Potential Fatty Acid Chemotherapeutic for Glioblastoma. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 159, 102142.	2.2	17
15	Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer. Frontiers in Nutrition, 2020, 7, 21.	3.7	35
16	Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. Communications Biology, 2019, 2, 200.	4.4	83
17	Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?. Neurochemical Research, 2019, 44, 2392-2404.	3.3	33
18	Perturbation of the yeast mitochondrial lipidome and associated membrane proteins following heterologous expression of Artemia-ANT. Scientific Reports, 2018, 8, 5915.	3.3	3

#	Article	IF	Citations
19	Mycoplasma infection and hypoxia initiate succinate accumulation and release in the VM-M3 cancer cells. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 975-983.	1.0	24
20	Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. ASN Neuro, 2018, 10, 175909141881826.	2.7	80
21	Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma. Frontiers in Nutrition, 2018, 5, 91.	3.7	12
22	Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up. Frontiers in Nutrition, 2018, 5, 20.	3.7	67
23	Out of Warburg effect: An effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Seminars in Cancer Biology, 2017, 43, 134-138.	9.6	108
24	Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutrition and Metabolism, 2017, 14, 19.	3.0	66
25	Ultrastructural characterization of the Mitochondria-associated membranes abnormalities in human astrocytomas: Functional and therapeutics implications. Ultrastructural Pathology, 2017, 41, 234-244.	0.9	36
26	Novel ketone body therapy for managing Alzheimer's disease. Journal of Neurochemistry, 2017, 141, 162-164.	3.9	5
27	Quantification of metastatic load in a syngeneic murine model of metastasis. Cancer Letters, 2017, 405, 56-62.	7.2	7
28	Environmental stimuli shape microglial plasticity in glioma. ELife, 2017, 6, .	6.0	51
29	The total and mitochondrial lipidome of Artemia franciscana encysted embryos. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1727-1735.	2.4	3
30	Cancer as a mitochondrial metabolic disease. Frontiers in Cell and Developmental Biology, 2015, 3, 43.	3.7	141
31	Myelin Abnormalities in the Optic and Sciatic Nerves in Mice With GM1-Gangliosidosis. ASN Neuro, 2015, 7, 175909141556891.	2.7	8
32	The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. Nutrition and Metabolism, 2015, 12, 12.	3.0	75
33	The role of metabolic therapy in treating glioblastoma multiforme. , 2015, 6, 61.		35
34	Bis(monoacylglycero)phosphate: a secondary storage lipid in the gangliosidoses. Journal of Lipid Research, 2015, 56, 1005-1006.	4.2	54
35	Bis(monoacylglycero)phosphate as a Macrophage Enriched Phospholipid. Lipids, 2015, 50, 907-912.	1.7	21
36	Influence of Serum and Hypoxia on Incorporation of [¹⁴C]â€<scp>d</scp>â€Glucose or [¹⁴C]â€<scp>l</scp>â€Glutamine into Lipids and Lactate in Murine Glioblastoma Cells. Lipids, 2015, 50, 1167-1184.	1.7	21

#	Article	IF	Citations
37	Metabolic therapy: A new paradigm for managing malignant brain cancer. Cancer Letters, 2015, 356, 289-300.	7.2	161
38	Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0143351.	2.5	32
39	Ketosis and hyperbaric oxygen metabolic therapy elicits potent antiâ€cancer effects in vitro and in vivo. FASEB Journal, 2015, 29, 725.13.	0.5	0
40	The Glucose Ketone Index Calculator: A Simple Tool to Assess Therapeutic Efficacy for Metabolic Management of Brain Cancer. FASEB Journal, 2015, 29, 897.15.	0.5	0
41	Influence of serum and hypoxia on endogenously synthesized lipids and lactate from radiolabeled glucose or glutamine in murine glioblastoma cells. FASEB Journal, 2015, 29, 568.16.	0.5	0
42	Glucose-dependent de Novo Lipogenesis in B Lymphocytes. Journal of Biological Chemistry, 2014, 289, 7011-7024.	3.4	138
43	GM1-gangliosidosis in American black bears: Clinical, pathological, biochemical and molecular genetic characterization. Molecular Genetics and Metabolism, 2014, 111, 513-521.	1.1	8
44	Autosomal Dominant Inheritance of Brain Cardiolipin Fatty Acid Abnormality in VM/DK Mice: Association with Hypoxicâ€induced Cognitive Insensitivity. Lipids, 2014, 49, 113-117.	1.7	4
45	Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 2014, 35, 515-527.	2.8	375
46	Meal frequency and timing in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16647-16653.	7.1	413
47	Ketone Strong: Emerging evidence for a therapeutic role of ketone bodies in neurological and neurodegenerative diseases. Journal of Lipid Research, 2014, 55, 1815-1817.	4.2	12
48	Influence of a ketogenic diet, fish-oil, and calorie restriction on plasma metabolites and lipids in C57BL/6J mice. Nutrition and Metabolism, 2014, 11, 23.	3.0	58
49	Glucose reduces the anticonvulsant effects of the ketogenic diet in EL mice. Epilepsy Research, 2014, 108, 1137-1144.	1.6	15
50	Ganglioside Storage Diseases: On the Road to Management. Advances in Neurobiology, 2014, 9, 485-499.	1.8	7
51	Ethylenedioxy-PIP2 Oxalate Reduces Ganglioside Storage in Juvenile Sandhoff Disease Mice. Neurochemical Research, 2013, 38, 866-875.	3.3	18
52	A Single Intravenous rAAV Injection as Late as P20 Achieves Efficacious and Sustained CNS Gene Therapy in Canavan Mice. Molecular Therapy, 2013, 21, 2136-2147.	8.2	77
53	Therapeutic Response in Feline Sandhoff Disease Despite Immunity to Intracranial Gene Therapy. Molecular Therapy, 2013, 21, 1306-1315.	8.2	71
54	On the Origin of Cancer Metastasis. Critical Reviews in Oncogenesis, 2013, 18, 43-73.	0.4	797

#	Article	IF	Citations
55	The ketogenic diet and hyperbaric oxygen therapy work synergistically to slow tumor growth and increase survival time in mice with systemic metastatic cancer. FASEB Journal, 2013, 27, 863.2.	0.5	1
56	The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer. PLoS ONE, 2013, 8, e65522.	2.5	160
57	Supplemental ketone metabolic therapy slows tumor growth and increases survival time in mice with metastatic cancer. FASEB Journal, 2013, 27, 863.1.	0.5	0
58	Influence of Dietary Intake on Plasma Metabolites and Lipids in C57BL/6J Mice. FASEB Journal, 2013, 27, 794.2.	0.5	1
59	Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer?. Epilepsy Research, 2012, 100, 310-326.	1.6	56
60	The EL mouse: A natural model of autism and epilepsy. Epilepsia, 2011, 52, 347-357.	5.1	21
61	Itaconic Acid Is a Mammalian Metabolite Induced during Macrophage Activation. Journal of the American Chemical Society, 2011, 133, 16386-16389.	13.7	277
62	Influence of Caloric Restriction on Constitutive Expression of NF-Î²B in an Experimental Mouse Astrocytoma. PLoS ONE, 2011, 6, e18085.	2.5	65
63	A Mathematical Model for the Determination of Steady-State Cardiolipin Remodeling Mechanisms Using Lipidomic Data. PLoS ONE, 2011, 6, e21170.	2.5	14
64	Metabolic management of brain cancer. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 577-594.	1.0	119
65	Lipid Composition of Whole Brain and Cerebellum in Hurler Syndrome (MPS IH) Mice. Neurochemical Research, 2011, 36, 1669-1676.	3.3	7
66	Biography of Dr. Robert K. Yu. Neurochemical Research, 2011, 36, 1575-1577.	3.3	0
67	Filipin recognizes both GM1 and cholesterol in GM1 gangliosidosis mouse brain. Journal of Lipid Research, 2011, 52, 1345-1351.	4.2	43
68	Hypothesis: Are Neoplastic Macrophages/Microglia Present in Glioblastoma Multiforme?. ASN Neuro, 2011, 3, AN20110011.	2.7	54
69	Perspectives on the mesenchymal origin of metastatic cancer. Cancer and Metastasis Reviews, 2010, 29, 695-707.	5.9	50
70	A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. Journal of Neuro-Oncology, 2010, 99, 165-176.	2.9	60
71	Cancer as a metabolic disease. Nutrition and Metabolism, 2010, 7, 7.	3.0	494
72	Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. International Journal of Cancer, 2010, 126, 65-72.	5.1	27

#	Article	IF	Citations
73	Glutamine targeting inhibits systemic metastasis in the VMâ€M3 murine tumor model. International Journal of Cancer, 2010, 127, 2478-2485.	5.1	97
74	Restricted ketogenic diet enhances the therapeutic action of Nâ€butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. Journal of Neurochemistry, 2010, 113, 1525-1535.	3.9	23
75	Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntingtonâ€™s disease. Journal of Neurochemistry, 2010, 115, 748-758.	3.9	36
76	Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer. Journal of Oncology, 2010, 2010, 1-8.	1.3	33
77	AAV-Mediated Gene Delivery in Adult GM1-Gangliosidosis Mice Corrects Lysosomal Storage in CNS and Improves Survival. PLoS ONE, 2010, 5, e13468.	2.5	70
78	Dynamic simulation of cardiolipin remodeling: greasing the wheels for an interpretative approach to lipidomics. Journal of Lipid Research, 2010, 51, 2153-2170.	4.2	62
79	Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Developmental Biology, 2010, 344, 1035-1046.	2.0	126
80	Does the existing standard of care increase glioblastoma energy metabolism?. Lancet Oncology, The, 2010, 11, 811-813.	10.7	43
81	Brain Lipid Analysis in Mice with Rett Syndrome. Neurochemical Research, 2009, 34, 1057-1065.	3.3	9
82	Comparative Analysis of Brain Lipids in Mice, Cats, and Humans with Sandhoff Disease. Lipids, 2009, 44, 197-205.	1.7	47
83	Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets. Epilepsy and Behavior, 2009, 15, 133-141.	1.7	58
84	In Vitro Growth Environment Produces Lipidomic and Electron Transport Chain Abnormalities in Mitochondria from Non-Tumorigenic Astrocytes and Brain Tumours. ASN Neuro, 2009, 1, AN20090011.	2.7	48
85	Brain Mitochondrial Lipid Abnormalities in Mice Susceptible to Spontaneous Gliomas. Lipids, 2008, 43, 951-959.	1.7	32
86	Metastatic cancer cells with macrophage properties: Evidence from a new murine tumor model. International Journal of Cancer, 2008, 123, 73-84.	5.1	81
87	Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets. Epilepsia, 2008, 49, 114-116.	5.1	45
88	Lipidomic analysis and electron transport chain activities in C57BL/6J mouse brain mitochondria. Journal of Neurochemistry, 2008, 106, 299-312.	3.9	128
89	Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Molecular Cancer, 2008, 7, 37.	19.2	86
90	N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochemistry International, 2008, 52, 1125-1133.	3.8	44

#	Article	IF	Citations
91	Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: A membrane proteomics approach. Cancer Letters, 2008, 263, 243-252.	7.2	62
92	Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. Journal of Lipid Research, 2008, 49, 2545-2556.	4.2	239
93	Differentiating N-linked glycan structural isomers in metastatic and nonmetastatic tumor cells using sequential mass spectrometry. Glycobiology, 2008, 18, 353-366.	2.5	45
94	Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2â€“Deficient Mouse Astrocytoma. Clinical Cancer Research, 2008, 14, 7751-7762.	7.0	72
95	Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. Journal of Lipid Research, 2008, 49, 929-938.	4.2	48
96	Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nature Medicine, 2007, 13, 439-447.	30.7	293
97	Neurochemical, morphological, and neurophysiological abnormalities in retinas of Sandhoff and GM1 gangliosidosis mice. Journal of Neurochemistry, 2007, 101, 1294-1302.	3.9	23
98	Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiology of Disease, 2007, 27, 265-277.	4.4	120
99	Behavioral seizure correlates in animal models of epilepsy: A road map for assay selection, data interpretation, and the search for causal mechanisms. Epilepsy and Behavior, 2006, 8, 5-38.	1.7	36
100	Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma. Journal of Neurochemistry, 2006, 98, 1973-1984.	3.9	25
101	Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. Journal of Neuroscience Research, 2006, 83, 1028-1038.	2.9	35
102	Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer, 2005, 5, 102.	2.6	27
103	Targeting energy metabolism in brain cancer: review and hypothesis. Nutrition and Metabolism, 2005, 2, 30.	3.0	195
104	Antiangiogenic and Proapoptotic Effects of Dietary Restriction on Experimental Mouse and Human Brain Tumors. Clinical Cancer Research, 2004, 10, 5622-5629.	7.0	149
105	Oxygenation Prevents Sudden Death in Seizureâ€prone Mice. Epilepsia, 2004, 45, 993-996.	5.1	110
106	Inheritance of Lysosomal Acid Î²-Galactosidase Activity and Gangliosides in Crosses of DBA/2J and Knockout Mice. Biochemical Genetics, 2004, 42, 241-257.	1.7	32
107	N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. Journal of Neurochemistry, 2004, 89, 645-653.	3.9	68
108	Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. Journal of Neurochemistry, 2003, 86, 529-537.	3.9	151

#	Article	IF	Citations
109	Caloric Restriction Inhibits Seizure Susceptibility in Epileptic EL Mice by Reducing Blood Glucose. Epilepsia, 2002, 42, 1371-1378.	5.1	162
110	Enhanced Aspartate Release Related to Epilepsy in (EL) Mice. Journal of Neurochemistry, 2002, 63, 592-595.	3.9	28
111	Inhibition of Glycosphingolipid Biosynthesis Does Not Impair Growth or Morphogenesis of the Postimplantation Mouse Embryo. Journal of Neurochemistry, 2002, 70, 871-882.	3.9	28
112	Expression of Mouse Sialic Acid on Gangliosides of a Human Glioma Grown as a Xenograft in SCID Mice. Journal of Neurochemistry, 2002, 73, 254-259.	3.9	26
113	Hippocampal neurons and glia in epileptic EL mice. Journal of Neurocytology, 2002, 31, 681-692.	1.5	58
114	Genes differentially expressed in the kindled mouse brain. Molecular Brain Research, 2001, 96, 94-102.	2.3	24
115	Perspectives on Brain Tumor Formation Involving Macrophages, Glia, and Neural Stem. Perspectives in Biology and Medicine, 2001, 44, 263-282.	0.5	50
116	Environmental Risk Factors for Multifactorial Epilepsy in EL Mice. Epilepsia, 1999, 40, 1697-1707.	5.1	62
117	Glycosphingolipid Biosynthesis May Not Be Necessary for Vertebrate Brain Developmenta. Annals of the New York Academy of Sciences, 1998, 845, 215-218.	3.8	4
118	Ganglioside composition of a mouse brain tumor grown in the severe combined immunodeficiency (SCID) mouse. Molecular and Chemical Neuropathology, 1998, 33, 27-37.	1.0	6
119	Environmental Influences on Epilepsy Gene Mapping in El Mice. Journal of Neurogenetics, 1998, 12, 67-86.	1.4	22
120	Nonallelism for the Audiogenic Seizure Prone (ASP1) and the Aryl Hydrocarbon Receptor (AHR) Loci in Mice. Journal of Neurogenetics, 1998, 12, 191-203.	1.4	6
121	Synaptic vesicle glutamate uptake in epileptic (EL) mice. Neurochemistry International, 1997, 31, 581-585.	3.8	15
122	Genomic imprinting and audiogenic seizures in mice. Behavior Genetics, 1997, 27, 465-475.	2.1	23
123	Influence of Host Cell Infiltration on the Glycolipid Content of Mouse Brain Tumors. Journal of Neurochemistry, 1996, 66, 2026-2033.	3.9	23
124	Influence of growth environment on the ganglioside composition of an experimental mouse brain tumor. Molecular and Chemical Neuropathology, 1994, 21, 273-285.	1.0	14
125	Ceruloplasmin gene defect associated with epilepsy in EL mice. Nature Genetics, 1994, 6, 426-431.	21.4	27
126	The influence of ImuVert, a biological response modifier, on the growth and ganglioside composition of murine neural tumors. Molecular and Chemical Neuropathology, 1993, 20, 163-172.	1.0	9

#	Article	IF	Citations
127	Influence of Audiogenic Seizures on Synaptic Facilitation in Mouse Hippocampal Slices Is Mediated by N-Methyl-d-Aspartate Receptor. Epilepsia, 1993, 34, 979-984.	5.1	16
128	Biochemical Correlates of Epilepsy in the El Mouse: Analysis of Glial Fibrillary Acidic Protein and Gangliosides. Journal of Neurochemistry, 1992, 58, 752-760.	3.9	39
129	Ganglioside distribution in murine neural tumors. Molecular and Chemical Neuropathology, 1992, 17, 147-167.	1.0	96
130	Neutral glycolipid abnormalities in at-complex mutant mouse embryo. Biochemical Genetics, 1992, 30, 557-565.	1.7	0
131	Kindling Susceptibility and Genetic Seizure Predisposition in Inbred Mice. Epilepsia, 1991, 32, 22-26.	5.1	31
132	Enhanced Aspartate Release from Hippocampal Slices of Epileptic (El) Mice. Journal of Neurochemistry, 1991, 56, 1007-1011.	3.9	69
133	Ganglioside GD3 biosynthesis in normal and mutant mouse embryos. Biochemical Genetics, 1991, 29, 627-638.	1.7	9
134	Mapping of two genes that influence susceptibility to audiogenic seizures in crosses of C57BL/6J and DBA/2J mice. Behavior Genetics, 1990, 20, 307-323.	2.1	65
135	Ganglioside GM1 Elevation in DBA/2 Mouse Embryos. Developmental Neuroscience, 1990, 12, 126-132.	2.0	7
136	Ganglioside Composition of Normal and Mutant Mouse Embryos. Journal of Neurochemistry, 1989, 52, 460-466.	3.9	43
137	Ganglioside abnormalities associated with failed neural differentiation in a T-locus mutant mouse embryo. Developmental Biology, 1987, 123, 286-291.	2.0	36
138	Immunocytochemical localization of GD3 ganglioside to astrocytes in murine cerebellar mutants. Brain Research, 1986, 374, 260-269.	2.2	49
139	Calcium ATPase Activities in Synaptic Plasma Membranes of Seizure-Prone Mice. Journal of Neurochemistry, 1986, 46, 1370-1375.	3.9	29
140	A Review of Mouse Mutants as Genetic Models of Epilepsy. Epilepsia, 1985, 26, 143-150.	5.1	171
141	Genetic Study of Cationic ATPase Activities and Audiogenic Seizure Susceptibility in Recombinant Inbred and Congenic Strains of Mice. Journal of Neurochemistry, 1984, 42, 529-533.	3.9	16
142	Genetic Association Between Ca2+-ATPase Activity and Audiogenic Seizures in Mice. Journal of Neurochemistry, 1984, 42, 1771-1774.	3.9	35
143	Cellular Distribution of Gangliosides in the Developing Mouse Cerebellum: Analysis Using the Staggerer Mutant. Journal of Neurochemistry, 1984, 43, 1152-1162.	3.9	60
144	GD3 ganglioside is a glycolipid characteristic of immature neuroectodermal cells. Journal of Neuroimmunology, 1984, 7, 179-192.	2.3	193

#	Article	IF	Citations
145	Genetic heterogeneity for the development of audiogenic seizures in mice. Brain Research, 1983, 271, 325-329.	2.2	26
146	Retinal Gangliosides in RCS Mutant Rats. Journal of Neurochemistry, 1982, 39, 277-279.	3.9	25
147	Differential Cellular Enrichment of Gangliosides in the Mouse Cerebellum: Analysis Using Neurological Mutants. Journal of Neurochemistry, 1982, 38, 551-559.	3.9	85
148	Cerebellar gangliosides and phospholipids in mutant mice with ataxia and epilepsy: the Tottering/Leaner syndrome. Brain Research, 1981, 216, 429-436.	2.2	48
149	GENETIC LINKAGE BETWEEN THE AH LOCUS AND A MAJOR GENE THAT INHIBITS SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN MICE. Genetics, 1981, 99, 117-126.	2.9	36
150	Heterosis for brain myelin content in mice. Biochemical Genetics, 1980, 18, 1229-1238.	1.7	33
151	GENETIC ANALYSIS OF AUDIOGENIC SEIZURE SUSCEPTIBILITY IN C57BL/6J x DBA/2J RECOMBINANT INBRED STRAINS OF MICE. Genetics, 1980, 94, 701-718.	2.9	62
152	Genetic variability for regional brain gangliosides in five strains of young mice. Biochemical Genetics, 1979, 17, 43-55.	1.7	44
153	CEREBRAL, CEREBELLAR, AND BRAIN STEM GANGLIOSIDES IN MICE SUSCEPTIBLE TO AUDIOGENIC SEIZURES. Journal of Neurochemistry, 1978, 31, 21-27.	3.9	113
154	Inheritance of brain weight in two strains of mice. Journal of Heredity, 1977, 68, 337-338.	2.4	7